Various muscarinic and antimuscarinic drugs act on the central nervous system and are used for therapeutic purposes. Electrophysiological studies have suggested that some of the neurons in this system are muscarinic (1, 2, 3) , and binding experiments using various muscarinic agonists and antagonists revealed the distribution of muscarinic receptors in the central nervous system (4, 5, 6) . It has also been suggested that there are presynaptic muscarinic receptors, which regulate acetylcholine (ACh) release at cholinergic synapses (7) .
However, recent findings cannot be explained on the basis of classical ideas on receptors .
Ariens and coworkers suggested that in many kinds of receptors agonists and antagonists may bind to different sites on the same receptor (8 suggested that atropine and ACh may bind to adjacent or overlapping sites rather than to the same site on receptors in guinea pig ileum (9) .
This paper describes differences in the bindings of ACh and atropine to synaptic plasma membranes from rat brain. of nonspecific bindings of the two ligands were estimated in a mixture containing 1,000 to 10,000-fold more of the unlabeled species of ligand, and the specific bindings were calculated by subtracting the nonspecific bindings from the total bindings.
MATERIALS AND METHODS

Determination of specific radioactivities
In this paper, the specific radioactivities of atropine and ACh have an important sig nificance because the amounts of the bindings were calculated by use of those values. The binding of 3H-atropine was compared with that of 3H-quinuclidinyl benzilate. The amounts of maximal specific bindings of both antagonists were the same. Thus we considered the data of specific activity correct. The specific radioactivity of ACh was calculated from the concentration determined by bioassay (the contraction of frog abdominal muscle) and the radioactivity of ACh separated from choline by high voltage electrophoresis (12) . The calculated value agreed with the supplied value. However, 87 % of total radioactivity was 3H-ACh at the end of the experiments for this report , one year after the purchase. We may have overestimated the K,) value of ACh-binding but not so the maximal bindings as the amounts of maximal binding were determined by specific radioactivity. Therefore, this fact will have no essential effect on following discussions.
RESULTS
Characteristics of ACh and atropine-bindings to synaptic plasma membranes
The bindings of the two ligands were completely reversible and reached quilibrium within 40 min at O 'C and the maximum amounts of atropine-bindings on incubation at 37'C, 20'C and O 'C were similar. Therefore, in binding experiments incubations were carried out for 1 hour at O 'C to minimize the hydrolysis of the ligands. We examined the hydrolysis of ACh under this condition at which 10-5M eserine was present. The hydrolysis of ACh during the incubation was less than 10;,, measured by high voltage electrophoresis.
In this paper the word `binding' indicates specific bindings, as described under Materials and Methods, unless otherwise noted. We defined the saturable bindings as specific bind ings, a word used widely, for these bindings have high affinity and were specific for muscarinic drugs as shown in following results and discussions. However, a small fraction (less than 10 %) of the bindings with higher affinity, non-detectable in our assay ststem, may be possibly present.
The constants of the two bindings are summarized in Table 1 The assay medium contained 100 mM NaCI, 50 mM Tris-HCI (pH 7.4), 1 mM CaC12, 10-, M eserine and about 300 ug protein of synaptic plasma mem branes in a final volume of 2 ml. After incubation at 0''C for 60 min the mixture was filtered through a membrane filter (0.45 u, 13 mm~). Inset: double recipro cal plot of the binding. Effects of sulfhydryl reagents on the two bindings Preincubation of the synaptic plasma membrane with 1 mM 5,5'-dithiobis (2-nitrobenzoic acid) (DTNB) for 20 min at 37'C increased the maximal content of ACh binding to about 1.5 x 10-12 moles/mg protein, a value similar to that for atropine-binding (Fig. 3A) . This increased binding seemed to be mainly muscarinic, because it was largely inhibited by atropine and oxotremorine (Fig. 3B, Fig. 7 ). The affinity for ACh was not affected by DTNB.
Neither the maximal content of atropine binding sites nor the affinity of sites for atropine was affected by DTNB (Fig. 4) . However, DTNB potentiated the inhibition of atropine binding by ACh about 10 times ( Inhibitions of the two bindings by cholinergic agents Fig. 6 shows the effects of agonists and antagonists on the binding of atropine (2 x 10-9M).
The concentrations for 50% inhibition of atropine binding (2 x 10-9 M) were ap proximately 2 x 10-9 M for atropine and methylatropine, 2x10-8 M for trihexyphenidyl, 2 x 10-6 M for oxotremorine, 1 x 10-5 M for ACh and 2 x 10-5 M for pilocarpine. Thus the inhibitory effects of these agonists on atropine-binding were weaker than their phar macological actions on the peripheral nervous system (the contraction of small intestine (14) and others) and KD value for ACh-binding to the synaptic plasma membranes (Table 1) . In contrast, the effects of antagonists were comparable in strength to their pharmacol ogical actions on peripheral nerves. Methylatropine had the same potency as atropine and trihexyphenidyl also strongly inhibited atropine-binding. The other cholinergic agents, d-tubocurarine, hemicholinium-3 and eserine inhibited atropine-binding slightly (less than 20% at concentrations of 10-5 M). Tremorine, which is inactive but is a precursor of oxotremorine, showed 50% inhibition at a concentration of 5 x 10-5 M. This concentration is about 25 times the concentration of oxotremorine required for the same effect, but we did not test whether the tremorine we used was contaminated with oxotremorine. Fig. 7 shows the effects of atropine and oxotremorine on ACh-binding (5 x 10-8 M).
Unlike atropine-binding, ACh-binding was inhibited by atropine and oxotremorine at con centrations comparable to those for their peripheral actions and KD for atropine-binding.
There were some fractions of ACh-binding which were inhibited entirely by oxotremorine but not by atropine (Fig. 3B, Fig. 7) . The inhibition by atropine was competitive, with a KI value of about 4 x 10-9 M (Fig. 8) . 
DISCUSSION
The present findings on the binding of atropine agree with those on muscarinic an tagonists reported by others (4, 6). Atropine-binding was inhibited by low concentrations of muscarinic antagonists but not by nicotinic antagonists. In contrast, ACh-binding was strongly inhibited by low concentrations of atropine and oxotremorine. The KD values of the two ligands obtained in the present study were comparable with the potencies of their peripheral muscarinic actions (14, 15) . It seems reasonable to assume that the muscarinic receptors in the central nervous system should have similar properties to those of receptors in the peripheral nervous system. Thus, we suggest that the bindings of the two ligands examined in the present study are bindings to muscarinic receptors. Moreover, under our conditions ACh-binding to nicotinic receptors is probably negligible since it has been reported that there are only one tenth as many nicotinic as muscarinic receptors in the brain (16) , and because in the peripheral nervous system, ACh is known to have a lower affinity for nicotinic receptors than for muscarinic receptors. It is difficult to consider that the part of ACh-binding which was not inhibited by atropine was nicotinic because oxotremorine which had no nicotinic action on frog striated muscle at the concentration to 10-4 M (not shown)
inhibited ACh-binding perfectly (Fig. 3B, Fig. 7 ) (15). Schleifer and Eldefrawi (5), in their study of the bindings of atropine and ACh to mouse brain measured by equilibrium dialysis, reported that the binding site to ACh was much less than that to atropine. The discrepancy between these results may be due to the long incubation (36 hr) for equilibrium dialysis used in their study. On nicotinic receptors, Call competes with agonists both in vivo and in vitro (18, 19) .
Muscarinic actions may be mediated by increase in permeability of the membranes to Call (20) . However, we found that removal of Call from the medium had no affect on atropine binding or on the inhibitory effect of ACh on atropine-binding.
Simantov and Snyder reported that monovalent cations have strong influences on an opiate receptor (21) . We found that replacement of Na+ in the medium by K+ or Li+ had no significant affect on the muscarinic receptors.
The membrane fraction contained fewer ACh-binding sites than atropine binding sites, but on preincubation with DTNB, the number of binding sites for ACh and for atropine became equal. Nicotinic receptors are known to contain a disulfide bond which plays an important role in the activity of these receptors (22) . Moreover, DTT and DTNB are known to cause breakdown and formation of disulfide bonds, respectively. Thus the receptors which are oxidized by DTNB may contain a disulfide bond in the physiological state, but during homogenization, disulfide bonds on the outer surface of plasma membranes may be reduced by thiol compounds in the intracellular fluid. However, we failed to mimic these effects using other disulfide compounds such as cystamine and cystine. Moreover, the possibility that the half to the DTNB molecule is bound to the thiol groups of the recep tors and that it has this pharmacological effect remains to be tested (23) . Nevertheless, in either case a thiol or disulfide group in the receptor plays an important role on the state of ACh-binding site.
Unlike ACh-binding, atropine-binding was not affected by DTNB. However, the inhibitory effect of ACh on atropine-binding was increased by pretreatment of the membranes with DTNB. It seems unlikely that the increases in ACh-binding and the inhibitory effect of ACh on atropine-binding are both due to a single effect on one site, because a high con centration of ACh was required to inhibit the binding of atropine, although ACh itself has high binding affinity. Thus the two actions of ACh may be due to the binding of ACh to different sites (Fig. 6, Table 1 ).
Ariens and Beld (18) suggested that many kinds of receptors may have two different sites for binding of an agonist and an antagonist and that muscarinic receptors also seem to have these two binding sites. Our data on the differences in sensitivities of the two bindings to DTNB and on the differences of the potencies of agonists and antagonists which inhibit the bindings of the other type of ligand support their suggestion. 
